Erratum to Prevalence of carbapenem-resistant organisms and other Gram-negative MDRO in German ICUs: first results from the national nosocomial infection surveillance system (KISS) (Infection, 10.1007/s15010-014-0701-6);Prevalence of carbapenem-resistant organisms and other Gram-negative MDRO in German ICUs: first results from the national nosocomial infection surveillance system (KISS)

Infection

Volumn 43, Issue 2, 2015, Pages 163-168

  Maechler, F ^a   Pena Diaz L A ^a   Schroder C ^a   Geffers, C ^a   Behnke, M ^a   Gastmeier, P ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Carbapenem resistant; Enterobacteriaceae; Gram negative; ICU; KISS; Multidrug resistant; Prevalence

Indexed keywords

CARBAPENEM DERIVATIVE;

ANTIBIOTIC RESISTANCE; BACTERIAL INFECTIONS; CLINICAL TRIAL; CROSS INFECTION; GERMANY; GRAM-NEGATIVE BACTERIAL INFECTIONS; HEALTH SURVEY; HUMAN; INCIDENCE; INTENSIVE CARE UNIT; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIOLOGY; MULTICENTER STUDY; MULTIDRUG RESISTANCE; PREVALENCE; STAPHYLOCOCCAL INFECTIONS; VANCOMYCIN RESISTANT ENTEROCOCCUS;

BACTERIAL INFECTIONS; BETA-LACTAM RESISTANCE; CARBAPENEMS; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GERMANY; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; INCIDENCE; INTENSIVE CARE UNITS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; POPULATION SURVEILLANCE; PREVALENCE; STAPHYLOCOCCAL INFECTIONS; VANCOMYCIN-RESISTANT ENTEROCOCCI;

EID: 84940002974     PISSN: 03008126     EISSN: 14390973     Source Type: Journal    
DOI: 10.1007/s15010-014-0712-3     Document Type: Erratum

References (25)

1. Antimicrobial resistance: global report on surveillance 2014. World Health Organization; 2014
2. Maragakis LL. Recognition and prevention of multidrug-resistant Gram-negative bacteria in the intensive care unit. Crit Care Med. 2010;38:S345–51. doi:10.1097/CCM.0b013e3181e6cbc5.
3. Tabah A, Koulenti D, Laupland K, Misset B, Valles J, Bruzzi de Carvalho, F et al. Characteristics and determinants of outcome of hospital-acquired bloodstream infections in intensive care units: the EUROBACT International Cohort Study. Intensive Care Med. 2012;38:1930–45. doi:10.1007/s00134-012-2695-9.
4. Lubbert C, Becker-Rux D, Rodloff AC, Laudi S, Busch T, Bartels M, et al. Colonization of liver transplant recipients with KPC-producing Klebsiella pneumoniae is associated with high infection rates and excess mortality: a case-control analysis. Infection. 2014;42:309–16. doi:10.1007/s15010-013-0547-3.
5. Gastmeier P, Sohr D, Schwab F, Behnke M, Zuschneid I, Brandt C, et al. Ten years of KISS: the most important requirements for success. J Hosp Infect. 2008;70:11–6. doi:10.1016/s0195-6701(08)60005-5.
6. DIN 58940-4, 4 (2004).
7. KRINKO. Kommission für Krankenhaushygiene und Infektionsprävention: hygienemaßnahmen bei Infektionen oder Besiedlung mit multiresistenten gramnegativen Stäbchen. Bundesgesundheitsbl. 2012;55:1311–54.
8. Infektionsschutzgesetz vom 20. Juli 2000 (BGBl. I S. 1045), das durch Artikel 5 Absatz 2 des Gesetzes vom 20. April 2013 (BGBl. I S. 868) geändert worden ist, Artikel 5 Absatz 2 (2000).
9. Meyer E, Schroder C, Gastmeier P, Geffers C. The reduction of nosocomial MRSA infection in Germany: an analysis of data from the Hospital Infection Surveillance System (KISS) between 2007 and 2012. Deutsches Arzteblatt int. 2014;111:331–6. doi:10.3238/arztebl.2014.0331.
10. Nordmann P, Cuzon G, Naas T. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis. 2009;9:228–36. doi:10.1016/s1473-3099(09)70054-4.
11. Marquez P, Terashita D, Dassey D, Mascola L. Population-based incidence of carbapenem-resistant Klebsiella pneumoniae along the continuum of care, Los Angeles County. Infect Control Hosp Epidemiol. 2013;34:144–50. doi:10.1086/669087.
12. Meyer E, Gastmeier P, Deja M, Schwab F. Antibiotic consumption and resistance: data from Europe and Germany. Int J Med Microbiol. 2013;303:388–95. doi:10.1016/j.ijmm.2013.04.004.
13. Biehl LM, Schmidt-Hieber M, Liss B, Cornely OA, Vehreschild MJ. Colonization and infection with extended spectrum beta-lactamase producing Enterobacteriaceae in high-risk patients—review of the literature from a clinical perspective. Crit Rev Microbiol. 2014;. doi:10.3109/1040841X.2013.875515.
14. Liss B, Vehreschild J, Cornely O, Hallek M, Fätkenheuer G, Wisplinghoff H, et al. Intestinal colonisation and blood stream infections due to vancomycin-resistant enterococci (VRE) and extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBLE) in patients with haematological and oncological malignancies. Infection. 2012;40:613–9.
15. Reddy P, Malczynski M, Obias A, Reiner S, Jin N, Huang J, et al. Screening for extended-spectrum β-lactamase-producing Enterobacteriaceae among high-risk patients and rates of subsequent bacteremia. Clin Infect Dis. 2007;45:846–52.
16. Ehrhard I, Karaalp AK, Hackel T, Holl G, Rodewald N, Reif U, et al. Prevalence of carbapenemase-producing bacteria in hospitals in Saxony, Germany. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz. 2014;57:406–13. doi:10.1007/s00103-013-1914-z.
17. Heudorf U, Gustav C, Mischler D, Schulze J. Healthcare associated infections (HAI), antibiotic use and prevalence of multidrug-resistant bacteria (MDRO) in residents of long-term care facilities: the Frankfurt HALT plus MDRO project 2012. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz. 2014;57:414–22. doi:10.1007/s00103-013-1927-7.
18. Lippmann N, Lubbert C, Kaiser T, Kaisers UX, Rodloff AC. Clinical epidemiology of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis. 2014;14:271–2. doi:10.1016/S1473-3099(14)70705-4.
19. Souli M, Galani I, Giamarellou H. Emergence of extensively drug-resistant and pandrug-resistant Gram-negative bacilli in Europe. Euro surveillance. 2008;13:19045.
20. Hombach M, Mouttet B, Bloemberg GV. Consequences of revised CLSI and EUCAST guidelines for antibiotic susceptibility patterns of ESBL- and AmpC beta-lactamase-producing clinical Enterobacteriaceae isolates. J Antimicrobiol Chemother. 2013;68:2092–8. doi:10.1093/jac/dkt136.
21. ARS. RKI: Antibiotika Resistenz Surveillance. 2014; https://ars.rki.de/Dateneinfuehrung.aspx Accessed 31.07.2014.
22. Kaase M, Anders A, Pfennigwerth N, Gatermann S. Report of the national reference laboratory for multidrug-resistant gramnegative bacteria on carbapenemases in Germany in 2013. ECCMID; Barcelona 2014.
23. Maechler F, Schwab F, Geffers C, Gropmann A, Gastmeier P. Infection control policies and ICU-acquired ESBL-cases in Germany: a cross-sectional questionnaire survey of 224 ICUs. ECCMID; Barcelona 2014.
24. Krankenhausstatistik-Grunddaten [database on the Internet]. Statistisches Bundesamt, Zweigstelle Bonn. 2014; http://www.gbe-bund.de/. Accessed: 27.06.2014.
25. Zuschneid I, Rucker G, Schoop R, Beyersmann J, Schumacher M, Geffers C, et al. Representativeness of the surveillance data in the intensive care unit component of the German nosocomial infections surveillance system. Infect Control Hosp Epidemiol. 2010;31:934–8. doi:10.1086/655462.